Health · 6 views
Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss
In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight…
Summary
In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not all populations are benefiting from this expansion. As GLP-1 use has increased, disparities in access to these drugs have widened significantly, according to a new study led by researchers at Boston University School of Public Health (BUSPH).
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Giving patients a greater voice in their diabetes careContinue reading
- Alzheimer's Test Results Delivered Digitally Didn't Increase DistressContinue reading
- Philadelphia neonatologist Joanna Parga-Belinkie on keeping babies safe from measlesContinue reading
- Reporters Talk Measles, Pediatric Care, and Democrats’ Post-Election Healthcare AgendaContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow